World CLL Day with Dr. Anderson

By Mary Ann Anderson, MBBS, PhD - Last Updated: September 19, 2023

Mary Ann Anderson, MBBS, PhD, of the Peter MacCallum Cancer Centre in Australia, discusses the importance of World Chronic Lymphocytic Leukemia (CLL) Day.

Expert Panel Discusses Clinical Data, Practice of BTK Inhibitor, B-Cell Lymphoma 2 Inhibitor Use in CLL

Andrew MorenoChronic Lymphocytic Leukemia | March 7, 2025

The several considerations involved with these agent classes make discussions with patients of treatment decisions crucial.

Stepping Forward in CLL: Novel Agents and BTKi/BCL2i Combination Strategies

Melissa BadamoChronic Lymphocytic Leukemia | March 6, 2025

BTKi/BCL2i combinations may change how CLL treatment is offered over a patient’s lifespan, said Kerry Rogers, MD.

CD5-Targeting CAR T-Cell Therapy Receives FDA Orphan Drug Designation for T-Cell Lymphoma Use

Andrew MorenoT-Cell Lymphoma | January 30, 2025

Therapy also in development for T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma.

FDA Approves In-Vitro Assay to Identify B-Cell Lymphomas, Plasma Cell Neoplasms

Andrew MorenoAggressive B-Cell Lymphoma | January 29, 2025

The single-slide test helps clinicians differentiate more than 60 subtypes of these diseases from normal immune response.

Comparing Risk Scores for Disease Progression in Untreated CLL

Melissa BadamoChronic Lymphocytic Leukemia | January 29, 2025

The IPS-E, CR0, AIPS-E, CLL-IPI, and Barcelona-Brno risk scores can predict time to first treatment in CLL patients.

World CLL Day with Dr. Anderson

Related Posts